在使用或不使用贝瓦西祖马布的阿特佐利祖马布后,初级和二级伪稳定性和进展
Saiabhiroop Govindu1, Prashanth Gowda1, Maishara Muquith1
1Divison of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Journal for immunotherapy of cancer
|January 16, 2026
概括
非典型的瘤反应如伪进展发生在接受免疫治疗的癌症患者中. 了解这些模式是治疗决策和生存结果的关键.
科学领域:
- 在瘤学瘤学.
- 免疫疗法研究 免疫疗法研究
- 临床试验分析
背景情况:
- 对免疫治疗的非典型瘤反应在治疗评估中提出了挑战.
- 了解伪稳定性/进展性对于临床决策至关重要.
研究的目的:
- 描述伪稳定性/进展的流行病学,临床影响和分子特征.
- 分析与贝瓦齐祖马布或没有贝瓦齐祖马布对阿特佐利祖马布的非典型反应.
主要方法:
- 从八个随机试验中对2980名患者进行了后期分析.
- 包括患有非小细胞肺癌,尿路细胞癌,细胞癌 (RCC) 和肝细胞癌的患者.
主要成果:
- 确定了两个模式:初级 (进展然后回归,7.7%-12.5%) 和二级 (控制然后进展然后回归,4.4%-10.8%).
- 结果因癌症类型和初始反应而异;临床因素无法预测.
- 基因组变化,包括RCC中的TSC1/2,与伪进展有关.
结论:
- 伪稳定性/进展发生在癌症类型的显著患者比例中.
- 结果取决于癌症类型和初始反应.
- 识别这些亚型的特征可以指导免疫治疗决策.
相关概念视频
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


